Novel biomarkers for targeting cancer immunotherapy

The evasion of immune destruction is very interesting. Do metastatic cells have a wider range of mechanisms to evade detection? Is the niche for secondary tumors less accessible to immune detection due to the evasion of recognition?

Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Novel biomarkers for targeting cancer immunotherapy

Larry H. Bernstein, MD, FCAP, Curator

LPBI

EFFICACY AND POTENCY TESTING: CELLULAR IMMUNITY
http://www.ablinc.com/efficacy_and_potency_testing-cellular_Immunity.php?gclid=CIGI953juMgCFcuQHwodtyUJ0w

ABL has decades of experience working with human and animal samples to determine the efficacy, activity, and potency of vaccines and therapeutics. Our animal facility is located in close proximity to our laboratories allowing for fresh samples to be delivered in a timely manner for testing in ABL’s laboratories. ABL has a wealth of experience processing many different types of samples (blood, fluids, tissues, washes, etc) and viably freezing cells for shipment or testing at a later date.

In our continuing effort to ensure we are providing our clients with reliable and consistent data, ABL has worked with some of the top academic labs and experts in the country to cross validate our assays and sample collection techniques. This helps give our clients the assurance that the information they receive from…

View original post 821 more words

Advertisements

One thought on “Novel biomarkers for targeting cancer immunotherapy

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s